专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

71. 发明申请

US20140002048A1 VOLTAGE BALANCING CONTROL METHOD FOR MODULAR MULTILEVEL CONVERTER 审中-公开
标题翻译：用于模块化多电平转换器的电压平衡控制方法
公开(公告)号：US20140002048A1
公开(公告)日：2014-01-02
申请号：US14005266
申请日：2011-10-31
申请人： Hui Pang , Zhiyuan He , Yan Zhao , Chunming Yuan , Dong Liu , Wenjin Li
发明人： Hui Pang , Zhiyuan He , Yan Zhao , Chunming Yuan , Dong Liu , Wenjin Li
IPC分类号： H02M11/00
CPC分类号： H02M11/00 , H02M7/483 , H02M2001/0003 , H02M2007/4835
摘要： The present invention relates to Voltage balancing control method for modular multilevel converter is characterized that, it includes some steps as follows:1) Determine the leg current direction is positive or negative;2) Find out the highest sub module on output state whose capacitor voltage amplitude is the maximum, and find out that on bypass state whose capacitor voltage amplitude is the minimum;3) Determine whether the sub module inputs or bypass operation; this method avoided switching arbitrariness of the sub module, and decreased the switching frequency of the sub module. The capacitor voltage balancing control of the sub module proposed by the method is more suitable to be applied in the field of high voltage and large capacity converter that has large numbers of sub modules.
摘要翻译：本发明涉及模块化多电平转换器的电压平衡控制方法，其特征在于包括以下步骤：1）确定支路电流方向为正或负; 2）找出电容器电压幅度最大的输出状态下的最高子模块，找出电容电压幅值最小的旁路状态; 3）确定子模块是否输入或旁路操作; 该方法避免了子模块的任意切换，降低了子模块的切换频率。该方法提出的子模块的电容电压平衡控制更适用于具有大量子模块的高压大容量转换器领域。

72. 发明申请

US20120303452A1 Method and Apparatus for Providing Context Attributes and Informational Links for Media Data 审中-公开
标题翻译：为媒体数据提供上下文属性和信息链接的方法和装置
公开(公告)号：US20120303452A1
公开(公告)日：2012-11-29
申请号：US13576755
申请日：2010-02-03
申请人： Wenwei Xue , Zhanjiang Song , Dong Liu , Jilei Tian , Yiming Ma
发明人： Wenwei Xue , Zhanjiang Song , Dong Liu , Jilei Tian , Yiming Ma
IPC分类号： G06F3/01 , G06F15/16 , G06Q30/02
CPC分类号： H04L51/02 , H04L51/04
摘要： Various embodiments include a method including receiving media data on an apparatus, and receiving one or more context attributes related to the apparatus or accessed by the apparatus. The method further includes determining whether the one or more context attributes relate to the media data, and causing, at least in part, display of the media data with the one or more context attributes that are determined to relate to the media data. Also, a method is provided that includes receiving media data on an apparatus, parsing the media data into one or more structured elements, determining one or more informational links that relate to the one or more structured elements of the media data, and causing, at least in part, display of the media data with the one or more informational links that are determined to relate to the one or more structured elements.
摘要翻译：各种实施例包括一种方法，包括在装置上接收媒体数据，以及接收与该装置相关或由该装置访问的一个或多个上下文属性。所述方法还包括确定所述一个或多个上下文属性是否与所述媒体数据相关联，以及至少部分地使用所确定的与所述媒体数据相关的一个或多个上下文属性显示所述媒体数据。此外，提供了一种方法，其包括在装置上接收媒体数据，将媒体数据解析为一个或多个结构化元素，确定与媒体数据的一个或多个结构化元素相关的一个或多个信息链接，至少部分地，与被确定为与一个或多个结构化元素相关联的一个或多个信息链接显示媒体数据。

73. 发明授权

US08304385B2 Macrocyclic tetrazolyl hepatitis C serine protease inhibitors 有权
标题翻译：大环四唑丙型肝炎丝氨酸蛋白酶抑制剂
公开(公告)号：US08304385B2
公开(公告)日：2012-11-06
申请号：US12270963
申请日：2008-11-14
申请人： Ying Sun , Dong Liu , Yat Sun Or , Zhe Wang
发明人： Ying Sun , Dong Liu , Yat Sun Or , Zhe Wang
IPC分类号： A61K38/00 , A61K31/33 , A61K38/12 , C07K5/08 , C07D513/00 , C07D245/00
CPC分类号： C07K5/0808 , A61K38/212 , A61K38/215 , C07K5/0812 , A61K2300/00
摘要： The present invention relates to compounds of Formula I, II, III or IV, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising a compound of the present invention.
摘要翻译：本发明涉及式I，II，III或IV化合物或其药学上可接受的盐，酯或前药：其抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。

74. 发明申请

US20120230406A1 MULTI-FORMAT VIDEO DECODER WITH VECTOR PROCESSING AND METHODS FOR USE THEREWITH 审中-公开
标题翻译：具有矢量处理的多格式视频解码器及其使用方法
公开(公告)号：US20120230406A1
公开(公告)日：2012-09-13
申请号：US13076536
申请日：2011-03-31
申请人： Indra Laksono , Kai Yang , Hongri Wang , Dong Liu , Xu Gang (Wilf) Zhao , Eric Young , Edward Hong
发明人： Indra Laksono , Kai Yang , Hongri Wang , Dong Liu , Xu Gang (Wilf) Zhao , Eric Young , Edward Hong
IPC分类号： H04N7/50 , H04N7/26
CPC分类号： H04N19/103 , H04N19/136 , H04N19/436 , H04N19/44 , H04N19/61 , H04N19/91
摘要： A video decoder includes an entropy decoding device that generates entropy decoded (EDC) data from an encoded video signal. A multi-format video decoding device generates a decoded video signal from the EDC data, the multi-format video decoding device having a plurality of modules that are implemented via a plurality of vector processor units.
摘要翻译：视频解码器包括从编码视频信号产生熵解码（EDC）数据的熵解码装置。多格式视频解码装置从EDC数据生成解码视频信号，多格式视频解码装置具有通过多个向量处理器单元实现的多个模块。

75. 发明申请

US20090220065A1 Method and apparatus for active speaker selection using microphone arrays and speaker recognition 有权
标题翻译：用于使用麦克风阵列和扬声器识别的主动扬声器选择的方法和装置
公开(公告)号：US20090220065A1
公开(公告)日：2009-09-03
申请号：US12074276
申请日：2008-03-03
申请人： Sudhir Raman Ahuja , Jingdong Chen , Yiteng Arden Huang , Dong Liu , Qiru Zhou
发明人： Sudhir Raman Ahuja , Jingdong Chen , Yiteng Arden Huang , Dong Liu , Qiru Zhou
IPC分类号： H04M3/56
CPC分类号： H04M3/569 , G10L17/00 , G10L2021/02166 , H04M2201/41 , H04M2203/5072
摘要： A method and apparatus for performing active speaker selection in teleconferencing applications illustratively comprises a microphone array module, a speaker recognition system, a user interface, and a speech signal selection module. The microphone array module separates the speech signal from each active speaker from those of other active speakers, providing a plurality of individual speaker's speech signals. The speaker recognition system identifies each currently active speaker using conventional speaker recognition/identification techniques. These identities are then transmitted to a remote teleconferencing location for display to remote participants via a user interface. The remote participants may then select one of the identified speakers, and the speech signal selection module then selects for transmission the speech signal associated with the selected identified speaker, thereby enabling the participants at the remote location to listen to the selected speaker and neglect the speech from other active speakers.
摘要翻译：用于在电话会议应用中执行主动扬声器选择的方法和装置示例性地包括麦克风阵列模块，扬声器识别系统，用户界面和语音信号选择模块。麦克风阵列模块将来自每个有源扬声器的语音信号与其他有源扬声器的语音信号分离，从而提供多个单独的扬声器的语音信号。扬声器识别系统使用常规扬声器识别/识别技术识别每个当前有效的扬声器。然后将这些身份发送到远程电话会议位置，以通过用户界面向远程参与者显示。然后，远程参与者可以选择所识别的扬声器中的一个，并且语音信号选择模块然后选择用于传输与所选择的所识别的扬声器相关联的语音信号，从而使远程位置的参与者能够听取所选择的说话者并忽略语音从其他有源音箱

76. 发明授权

US07582605B2 Phosphorus-containing hepatitis C serine protease inhibitors 有权
标题翻译：含磷的丙型肝炎丝氨酸蛋白酶抑制剂
公开(公告)号：US07582605B2
公开(公告)日：2009-09-01
申请号：US11503407
申请日：2006-08-11
申请人： Joel D. Moore , Deqiang Niu , Guoyou Xu , Dong Liu , Yat Sun Or , Zhe Wang
发明人： Joel D. Moore , Deqiang Niu , Guoyou Xu , Dong Liu , Yat Sun Or , Zhe Wang
IPC分类号： A61K38/06 , C07K5/08
CPC分类号： A61K38/21 , C07K5/06191 , C07K5/0804 , A61K2300/00
摘要： The present invention relates to phosphorus-derived compounds of Formula I or Formula II, or a pharmaceutically acceptable salt, ester, or prodrug, thereof, which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
摘要翻译：本发明涉及抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶活性的式I或式II的磷衍生化合物或其药学上可接受的盐，酯或前药。因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。

77. 发明申请

US20090180981A1 QUINOXALINYL DERIVATIVES 有权
标题翻译：喹喔啉衍生物
公开(公告)号：US20090180981A1
公开(公告)日：2009-07-16
申请号：US12327538
申请日：2008-12-03
申请人： Deqiang Niu , Dong Liu , Joel D. Moore , Guoyou Xu , Ying Sun , Yonghua Gai , Datong Tang , Yat Sun Or , Zhe Wang
发明人： Deqiang Niu , Dong Liu , Joel D. Moore , Guoyou Xu , Ying Sun , Yonghua Gai , Datong Tang , Yat Sun Or , Zhe Wang
IPC分类号： A61K38/21 , C07K5/12 , A61K38/12 , A61P31/12
CPC分类号： C07D487/04 , A61K38/212 , A61K38/215 , C07K5/06165 , C07K5/0812 , A61K2300/00
摘要： The present invention relates to compounds of Formula I or II, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising a compound of the present invention.
摘要翻译：本发明涉及式I或II的化合物或其药学上可接受的盐，酯或前药：其抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。

78. 发明申请

US20090130059A1 TETRAZOLYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS 失效
标题翻译：四氢大环内酯类抗生素C丝氨酸蛋白酶抑制剂
公开(公告)号：US20090130059A1
公开(公告)日：2009-05-21
申请号：US12016659
申请日：2008-01-18
申请人： Ying Sun , Dong Liu , Yat Sun Or , Zhe Wang
发明人： Ying Sun , Dong Liu , Yat Sun Or , Zhe Wang
IPC分类号： A61K38/21 , A61K38/12
CPC分类号： C07K5/0804 , A61K31/13 , A61K31/41 , A61K31/7056 , A61K38/212 , A61K38/215 , A61K45/06 , C07D487/04 , A61K2300/00
摘要： The present invention relates to compounds of Formula I, II, III or IV, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising a compound of the present invention.
摘要翻译：本发明涉及式I，II，III或IV化合物或其药学上可接受的盐，酯或前药：其抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。

79. 发明申请

US20090035268A1 TETRAZOLYL ACYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS 审中-公开
公开(公告)号：US20090035268A1
公开(公告)日：2009-02-05
申请号：US11832096
申请日：2007-08-01
申请人： Ying Sun , Dong Liu , Yat Sun Or , Zhe Wang
发明人： Ying Sun , Dong Liu , Yat Sun Or , Zhe Wang
IPC分类号： A61K38/21 , C07D257/04 , A61K31/41 , A61P31/12 , A61K31/7056
CPC分类号： C07K5/0808 , A61K38/21 , A61K2300/00
摘要： The present invention relates to compounds of Formula I, II, III or IV, or pharmaceutically acceptable salts, esters or prodrugs thereof: which can inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising a compound of the present invention.

80. 发明申请

US20090005387A1 QUINOXALINYL MACROCYCLIC HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS 审中-公开
标题翻译：喹喔啉大环内酯类抗生素C病毒丝氨酸蛋白酶抑制剂
公开(公告)号：US20090005387A1
公开(公告)日：2009-01-01
申请号：US12016599
申请日：2008-01-18
申请人： Deqiang Niu , Dong Liu , Joel D. Moore , Guoyou Xu , Ying Sun , Yonghua Gai , Datong Tang , Yat Sun Or , Zhe Wang
发明人： Deqiang Niu , Dong Liu , Joel D. Moore , Guoyou Xu , Ying Sun , Yonghua Gai , Datong Tang , Yat Sun Or , Zhe Wang
IPC分类号： A61K31/495 , A61K31/497 , A61P31/00
CPC分类号： A61K31/497 , A61K31/495 , A61K38/13 , A61K38/212 , A61K38/215 , C07D245/04 , C07D403/12 , C07D487/04 , A61K2300/00
摘要： The present invention relates to compounds, including compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
摘要翻译：本发明涉及包括式I化合物或其药学上可接受的盐，酯或前药的化合物，其抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式